This research develops a novel PEG-free lipid nanoparticle for gene therapy. Unlike conventional nanoparticles, which trigger immune responses after repeated use, the new formulation remains stable without PEG and performs even better. The approach could enable safer repeat dosing, improve treatment effectiveness, and expand access to life-changing gene therapies.

This research improves drug formulations by developing predictive tools for amorphous solid dispersions that increase drug solubility while allowing higher drug loading in a single tablet. The work aims to reduce pill burden, improve medication adherence, lower pharmaceutical development costs, and make treatments more effective for patients with chronic illnesses.

This research develops orally administered nanoparticle therapies for metronomic chemotherapy in ovarian cancer. By delivering smaller drug doses directly to tumours over extended periods, it aims to reduce side effects, overcome drug resistance, improve patient quality of life, and make long-term cancer treatment easier and more effective.